Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference being held from November 10-12, 2025 in Boston.

Details of the event are as follows:

Date: Tuesday, November 11, 2025

Time: 3:00 p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Contacts

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  224.29
-6.01 (-2.61%)
AAPL  271.33
+1.63 (0.60%)
AMD  258.47
-5.86 (-2.22%)
BAC  53.03
+0.45 (0.87%)
GOOG  284.01
+8.84 (3.21%)
META  667.88
-83.79 (-11.15%)
MSFT  523.76
-17.79 (-3.29%)
NVDA  202.73
-4.31 (-2.08%)
ORCL  259.61
-15.69 (-5.70%)
TSLA  441.94
-19.57 (-4.24%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.